Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology ...

Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...

Ascend Advanced Therapies today makes public data demonstrating the performance of two proprietary manufacturing enhancers ...

MILAN - Genenta Science (NASDAQ:GNTA), a clinical-stage biotech company with a market capitalization of $61.84 million, and Anemocyte announced Friday a strategic collaboration focused on ...

Genenta Science S.p.A. initiating with a Buy rating following a 90% stock surge after announcing a strategic partnership with ANEMOCYTE for LVV plasmid DNA technology. GNTA's lead cell therapy, ...

A new platform developed at Scripps Research enables fast, scalable protein evolution. This potentially opens the door to new therapies and diagnostics. In addition, the technology may aid scientists ...

Learn how advances in stabilization, automation, and SR-DLS are making PEI-based transient transfection more efficient, ...

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms ...

The Class 12 Biology sample paper covers topics like competition, recombinant DNA technology, immunity, and population ...

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

NexCAR19, the world’s first humanised CAR-T therapy developed in India, has made gene therapies affordable and accessible ...